Performance of a Global Functional Assay Based on Interferon-γ Release to Predict Infectious Complications and Cancer After Kidney Transplantation

Transpl Int. 2024 Oct 30:37:13551. doi: 10.3389/ti.2024.13551. eCollection 2024.

Abstract

The QuantiFERON-Monitor assay (QTF-Monitor) is intended to assess innate and adaptive immune responses by quantifying interferon (IFN)-γ release upon whole blood stimulation with a TLR7/8 agonist and an anti-CD3 antibody. We performed the QTF-Monitor in 126 kidney transplant recipients (KTRs) at different points during the first 6 post-transplant months. The primary outcome was overall infection, whereas secondary outcomes included bacterial infection, opportunistic infection and de novo cancer. The association between IFN-γ production and outcomes was analyzed as "low" immune responses (<15 IU/mL) and as a continuous variable to explore alternative thresholds. There were no significant differences in the occurrence of overall infection according to the QTF-Monitor at any monitoring point. Regarding secondary outcomes, KTRs with a low response at week 2 experienced a higher incidence of bacterial infection (50.8% versus 24.4%; P-value = 0.006). Low response at month 1 was also associated with opportunistic infection (31.6% versus 14.3%; P-value = 0.033). The discriminative capacity of IFN-γ levels was poor (areas under the ROC curve: 0.677 and 0.659, respectively). No differences were observed for the remaining points or post-transplant cancer. In conclusion, the QTF-Monitor may have a role to predict bacterial and opportunistic infection in KTRs when performed early after transplantation.

Keywords: functional; immune monitoring; infection; kidney transplantation; prediction.

MeSH terms

  • Adult
  • Aged
  • Bacterial Infections / etiology
  • Female
  • Humans
  • Interferon-gamma Release Tests
  • Interferon-gamma* / metabolism
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Neoplasms*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / immunology
  • Postoperative Complications / etiology
  • Prospective Studies

Substances

  • Interferon-gamma

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Instituto de Salud Carlos III (ISCIII) through the projects PIE13/00045, PI19/01300, and PI22/01062, and co‐funded by the European Union. MF-R has hold a contract “Miguel Servet” (CP18/00073) from the ISCIII, Spanish Ministry of Science and Innovation. This study was partially presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which was held in Lisbon, Portugal, from 23 to 26 April 2022 (oral communication O0842).